Enhancer boosts psilocin potential in psychedelic therapy to treat PTSD

Canadian company NeuroPharm Inc. files application with the U.S. Patent and Trademark Office in connection with a psychedelic therapy.

MDMA shows potential in PTSD treatment; more research needed on other psychedelics

Australian researchers review the state of the evidence for using these drugs in the treatment of post-traumatic stress disorder

Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

Numinus Wellness chief medical officer Dr. Evan Wood cautions that it’s not a cure for everybody—but trials have shown statistically significant results

Cusp of breakthrough: clinical trial data suggest efficacy of MDMA therapy for PTSD

Clinical trials of MDMA psychotherapy are going on at 15 sites in the U.S., Canada, and Israel